Background: Numerous epidemiological research and investigations have been done discussing the connection between malignancies and antiphospholipid antibodies. Several investigations have shown that hematological malignancies may be related with the development of antiphospholipid antibodies but do not always enhance thrombotic risk in these patients.    Objective: The aim of the current work was to evaluate the association of lymphoproliferative disorders and thrombosis evident by duplex in clinically asymptomatic patients and how it relates to having antiphospholipid antibodies. Patients and methods: Study was conducted on 46 patients with lymphoproliferative disorders diagnosed by either lymph node biopsy or bone marrow aspirate, biopsy and immunophenotyping. Patients were recruited from Kasr Alainy Clinical Hematology Department from July 2020 to May 2022. These patients performed duplex on mesenteric and lower limb vessels to detect recent thrombosis or evidence of old thrombotic events. The patients were also investigated for PTT, lupus anticoagulants (LA), antibodies of B2 glycoprotein I, anticardiolipin, complete blood picture (CBC), and kidney and liver function tests.  Results: Mean age of the studied group was 51.17±13.22 years with 52.2% males and 47.8% females. Twelve (26.1%) of patients showed evidence of thrombosis or remnant of thrombus and recanalization, all of them had no clinical symptoms while the rest of the patients; 34 (73.9%) revealed no signs of thrombosis. There was no relation between the positively found antiphospholipid antibodies and thrombosis in the studied population.                                                             Conclusion: It could be concluded that there is evidence of increased thrombosis in patients with lymphoproliferative disorders, but no statistically significant correlation in relation to lymphoproliferative diseases and antiphospholipid antibodies.